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http://dx.doi.org/10.1016/j.jacl.2012.1BACKGROUND: The treatment of familial hyperchylomicronemia presenting in early childhood
with episodes of pancreatitis has been ineffective, and affected patients remain at risk for pancreatitis.
OBJECTIVE: To report on the effect of orlistat in siblings with severe inherited hyperchylomicrone-
mia and to assess posttreatment lipoprotein concentrations and composition.
METHODS: Serial observations of plasma lipid levels and hospitalizations after treatment with orli-
stat and lipoprotein studies on a single fasting posttreatment sample.
RESULTS: The affected siblings inherited a lipoprotein lipase gene mutation from each of their par-
ents: a novel mutation from their father (c.542G . C, p.G181R) and a known missense mutation from
their mother (c.644G . A, p.G215E). When the boy presented to us at age 9 years of age and his sister
at age 7 years, we found that addition of orlistat, a pancreatic lipase inhibitor, at a dose of 120 mg given
before three low-fat meals a day was effective in reducing episodes of pancreatitis in the boy and in
maintaining the triglyceride at lower levels in both children. During treatment, the children were ob-
served to have elevations in apolipoprotein (apo)B, low-density lipoprotein particle concentration, ab-
normal apoB-containing subclasses, and deficiencies in apoA-I and apoA-II-containing lipoproteins,
changes consistent with continuing increased cardiovascular risk.
CONCLUSION: The data support the need for more effective long-term treatments that not only pre-
vent pancreatitis but also offset cardiovascular risk. Orlistat can be considered effective in augmenting
the effect of a low-fat diet and reducing risk for pancreatitis.
 2013 National Lipid Association. Open access under CC BY-NC-ND license.t
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Open access under CC BY-NCFamilial chylomicronemia, although rare (affecting 1 in
1,000,000),1,2 presents in patients as severe lipemia associ-
ated with triglyceride levels greater than 2000 mg/dL and
recurrent pancreatitis even with stringent dietary fat restric-
tion.3 Conventional triglyceride-lowering agents that down--ND license.
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and enhance lipoprotein lipase such as fibrates and
omega-3 fatty acids usually have been ineffective because
VLDL is seldom elevated and lipoprotein lipase remains
defective.2 Recent trials of incorporating the lipoprotein li-
pase gene into muscle using the adeno-associated viral
vector-1 coupled to a gain-of-function lipoprotein lipase
gene variant (AAV1-LPLS447X) have been encouraging.
Initial results showed that a single administration of multi-
ple intramuscular injections given under spinal anesthesia
transiently lowered triglyceride levels for 5 months4; how-
ever, postprandial chylomicron clearance was improved by
93% at 14 weeks.5 This therapy is considered to be in a de-
velopmental phase, only achieving partial success,4,6 and
the long-term effectiveness and potential for the develop-
ment of this treatment method is unclear.
We present evidence that hyperchylomicronemia can be
improved and the risk for pancreatitis can be reduced by the
administration of orlistat (Xenical; Genentech, South San
Francisco, CA), a pancreatic lipase inhibitor given before
meals in affected siblings on a fat-restricted diet. In
addition to documenting reduction in fasting triglyceride,
we also studied the status of the remaining lipoprotein
profile to determine whether lipoproteins with atheroscle-
rotic characteristics are present in the affected children and
their carrier parents.Subjects
Case 1
A 12-year-old boy first presented at 3 months of age. His
plasma was found to be lipemic during a preoperative
evaluation for perirectal abscess. Subsequently, he experi-
enced recurrent abdominal pain, and triglyceride levels
increased to .13,000 mg/dL in the first year. Fat was
restricted to less than 10 g per day, and medium-chain
triglycerides were added.
At age 2 years 10 months, the patient’s triglyceride
levels were 1264 mg/dL, cholesterol 178 mg/dl, and high-
density lipoprotein cholesterol (HDL-C) 11 mg/dL.Table 1 Lipid values in the affected siblings before and after orlista
patient) and 31 months (boy patient)
Girl B
Months TG, mg/dL TC, mg/dL TG:TC HDL-C, mg/dL M
0† 2820 320 8.8 10
6 570 215 2.6 13 1
17 504 196 2.6 17 2
3
HDL-C, HDL-cholesterol; TC, total cholesterol; TG, fasting triglycerides; TG:
*Patient had acute pancreatitis.
†Orlistat treatment commenced.Apolipoprotein (Apo)C-II was reported to be present.
Amylase was 68 (25–125) and lipase 20 U/L (10–140).
He first developed pancreatitis at age 5 years and had
eruptive xanthomata. He presented to our clinic at the age
of 8 years and was admitted to the hospital with mild acute
pancreatitis and a history of 14 previous episodes of
pancreatitis requiring hospital admissions. Triglyceride
levels were 2670 mg/dL, cholesterol 1370 mg/dL, and
HDL-C 10 mg/dL. Magnetic resonance imaging showed
that the head of the pancreas appeared large and edematous;
peripancreatic fluid tracked to the right of the abdomen, a
short segment of regional colon was thickened, and there
were lymph nodes seen in the right upper and lower
quadrants consistent with inflammation.
After restriction of all oral intake and treatment with
intravenous fluids, he was placed on restricted fat intake to
less than 20 g per day with supplemental vitamins A, D, E,
and K; vitamin C; beta-carotene; and orlistat 120 mg before
meals. During the following year, he had only one episode
of pancreatitis and has been symptom-free over the past 3
years, except for occasional oily stool leakage and flatu-
lence. Lipase and amylase activities have remained normal.
The fasting triglyceride levels under home conditions has
ranged from 500 to 600 mg/dL over 31 months (Table 1),
but the fasting triglyceride was increased on the day of
the study (at age 12 years) after they had stayed at a nearby
hotel overnight (Table 2). Body mass index (BMI) was
18.9, and there were no abnormal physical findings. He
had attained Tanner stage 2 for puberty. Vitamin levels
(with normal ranges) while the patient was receiving sup-
plemental treatment were as follows: vitamin A, 26 mg/
dL (18–77), vitamin E, 23 mg/dL (4.6–17.8), vitamin K,
5.02 ng/dL (0.28–1.78), and 25(OH)D, 20 ng/mL (30–
100). The dose of vitamin D subsequently was increased
to 800 mIU per day.
Case 2
A 10-year-old girl, the younger sister of case 1, first
presented in the newborn nursery with a triglyceride level
of .500 mg/dL, which increased to .15,000 mg/dL after
the first month while she was breastfed. She was treatedt treatment given as 120 mg before meals during 17 months (girl
oy
onths TG, mg/dL TC, mg/dL TG:TC HDL-C, mg/dL
0*,† 2670 370 7.2 10
4 960 173 5.5 14
0 549 123 4.5 16
1 515 144 3.6 15
TC, triglycerides to cholesterol ratio.
Table 2 Lipids and apolipoproteins
Girl Boy Mother Father Normal 6 SD*
Triglycerides, mg/dL
Total 2180† 1225† 136 247† 84.8 6 42.8
Chylomicron 1337† 457† None
Chylomicron-free 803† 768† 84.8 6 42.8
Cholesterol, mg/dL
Total 250† 185 195 206 168.6 6 33.2
Chylomicron 120 102 None
Chylomicron-free 130 83 168.6 6 33.2
HDL-C, mg/dL 38 17 65 42 53.3 6 15.2
ApoA-I, mg/dL
Total 197† 131 143 126 132.3 6 17.7
Chylomicron 90.9† 46.5† None
Chylomicron-free 106.1 84.5 132.3 6 17.7
ApoA-II, mg/dL
Total 105.2† 129.6† 45.8 41.7 39.8 6 8.0
Chylomicron 76.7† 101.6† None
Chylomicron-free 28.5 28 39.8 6 8.0
ApoB, mg/dL
Total 403.5† 266.5† 81.3 97.1† 87.6 6 12.7
Chylomicron 270.5† 157.5† None
Chylomicron-free 133† 106.3† 87.6 6 12.7
ApoC-III, mg/dL
Total 126† 79† 10.6 12.4 9.5 6 2.6
Chylomicron 106.7† 69.5† None
Chylomicron-free 19.3† 9.5 9.5 6 2.6
C-III HP (chylomicron-free)‡ 6.4 7.9 3.1 6.7 3.4 6 1.7
C-III HS (chylomicron-free) 2.7 8.8 6.8 5.0 6.1 6 2.2
C-III ratio 0.42† 1.11† 2.19 0.75† 2.0 6 0.9
ApoE, mg/dL
Total 36.5† 53† 3.6 6.5 5.4 6 1.2
Chylomicron 32.5† 49.2† None
Chylomicron-free 4 3.8 5.4 6 1.2
Apo, apolipoprotein; HDL-C, HDL-cholesterol.
*Normal values were obtained from an adult control population (n 5 60).
†Abnormal values.
‡Heparin-manganese was used to separate apoB-containing particles in the precipitate (HP) from apoA-I-containing particles in the supernate (HS).
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chain triglycerides. At 6 years and 11 months, triglyceride
levels were 2820 mg/dL, cholesterol 320 mg/dL, HDL-C
10 mg/dL, and lipase 23 U/L without symptoms. She was
treated with orlistat 120 mg before meals and remains
symptom-free except for one admission to the hospital for
abdominal pain associated with normal lipase and amylase
values and a benign course. Follow-up fasting triglyceride
levels performed under home conditions have been below
600 mg/dL at two follow-up visits during a 17-month
period (Table 1), but at the time of the study, after an over-
night stay near the hospital, her triglyceride level was 2180
mg/dL (Table 2). Her BMI was 20.7, and there were no ab-
normal physical findings. She had attained Tanner stage 2
for puberty. Vitamin levels for the patient’s supplemental
treatment were as follows: vitamin A, 28 mg/dL (18–77);
vitamin E, 26.5 mg/dL (4.6–17.8); vitamin K, 3.55 ng/mL
0.28–1.78); and 25(OH)D, 27 ng/mL (30–100). As withher brother, the dose of vitamin D was increased to
800 mIU/day.
Family history
The mother’s sister developed pancreatitis associated
with hypertriglyceridemia at the age of 40 years. The
paternal grandfather and the grand-father’s three siblings
have moderately high triglyceride levels. Both parents have
a rural lifestyle and have been otherwise healthy. The
mother’s BMI was 23.5 and the father’s was 32.0.
Laboratory methods
A protocol for the studies was approved by the Institu-
tional Review Board at the University of Oklahoma Health
Sciences Center, and informed consent was obtained from
the participating family members. The study met
Blackett et al Orlistat for Familial Chylomicronemia 135requirements for exemption from investigational new drug
approval as determined by the Food andDrugAdministration
because we were in compliance with requirements for
institutional review and informed consent. Blood samples
were obtained after an overnight fast for more than 12 hours.
Baseline fasting pretreatment sampleswere obtained at clinic
visits, but samples for routine clinical follow-up were
conducted locally (Table 1). Samples for detailed lipoprotein
studies (Tables 2, 3, and 4) were also obtained fasting after an
overnight stay near the medical center in Oklahoma City.
Gene studies
Total genomic DNA was extracted from peripheral white
blood cells by the use of a QuickGene Automated extractor
(Autogen, Holliston, MA). mRNA was isolated from leuko-
cytes using a QIAamp RNA Blood Mini Kit (QIAGEN,
Valencia, CA). The first-strand cDNAwas reverse-transcribed
using a SuperScript III Reverse Transcriptase Kit (Invitrogen,
Carlsbad, CA) and random primers. Polymerase chain reac-
tion was performed using a touchdown program and the
designed primers corresponded to the coding region and the
flanking areas of apoC-II and lipoprotein lipase (LPL) genes.
The dideoxy nucleoside triphosphate terminator reaction
(ddNTP) was performed with an ABI BigDye Terminator
v3.1 Cycle Sequencing kit (Applied Biosystems). Sequencing
data were collected by the ABI 3130xl genetic analyzer (Ap-
plied Biosystems) for APOC2 and LPL.
Lipids and apolipoproteins
An Abbott VP-Super System automatic analyzer and
commercial reagents were used to determine levels of
cholesterol (Boehringer, Mannheim, Federal German Re-
public) and triglyceride (Miles Inc., Tarytown, NJ) by
enzymatic methodology. HDL-C was measured following
the heparin-manganese precipitation procedure of the Lipid
Research Clinics program, and low-density lipoprotein
cholesterol (LDL-C) was calculated by the Friedewald
formula. ApoA-I, apoB, and apoC-III were determined by
standardized immunoturbidimetric methods using polyclo-
nal antibodies.7 ApoC-II and apoE were measured by elec-
troimmunoassay. Assays on plasma from the affected boyTable 3 Lipoprotein subclasses according to apolipoprotein conten
Girl
(chylomicron-free)
Boy
(chylomicron-fre
LpA-II:B:C:D:E 25.3† 30.2†
LpB:E 1 LpB:C:E 14.3 12.5
LpB:C 10.4 30.7†
LpB 56.3 59.6
LpA-I 19.6† 23.8†
LpA-I:A-II 64.9† 82.3†
Lp, lipoprotein.
*Normal values were obtained from a local adult control population (n 5
†Abnormal values.and girl were done with and without the chylomicrons.
Chylomicrons were removed after the sample had remained
standing for more than 12 hours to obtain chylomicron-free
plasma. The assays were conducted at the Oklahoma Med-
ical Research Foundation in the laboratory of Petar Alau-
povic, PhD.
Apolipoprotein-based lipoprotein subclasses (LpB,
LpB:C, LpB:E 1 LpB:C:E, and LpA-II:B:C:D:E) were
determined by sequential immune precipitations.8 ApoB-
containing subclasses were performed in three separate
steps on the basis of sequential immunoprecipitation of
whole plasma by polyclonal antisera to apoA-II, apoE,
and apoC-III, respectively. To simplify the procedure, the
LpB:E and LpB:C:E subclasses were measured together.
The preparation of antisera was carried out according to a
previously described procedure.9 Lipoprotein subclass sizes
and concentrations were determined by nuclear magnetic
resonance by Liposcience Incorporated.10Results
LPL gene mutations
No variants were detected in the apoC-II gene (APOC2).
Compound heterozygous mutations c.542G . C
(p. G181R) and c.644G . A(p.G215E) were found in
exon 5 of the lipoprotein lipase gene of both children.
The parental samples were sequenced to determine the mu-
tations in cis or trans. G181R observed in the father, is a
novel missense mutation; and the missense mutation,
G215E observed in the mother has been described previ-
ously (Human Gene Mutation Database). Both mutations
also were confirmed at the mRNA level proving compound
heterozygous inheritance of the two alleles in both children.
Lipids and apolipoproteins
The triglyceride-lowering effect is shown over
17 months in our female patient and over 31 months in
our male patient (Table 1). Fasting triglyceride values dur-
ing treatment with orlistat (120 mg orally before meals) de-
creased from values greater than 2000 mg/dL to less thant
e) Mother Father Normal, mean 6 SD*
7.3 14.7 11.5 6 65.9
14.6 14.5 11.1 6 4.0
4.8 9.3 8.1 6 3.7
54.6 58.6 57.1 6 7.3
34 27.6† 34.5 6 5.3
109 98.4 97.8 6 13.7
60, ages 18–72, mean 40 6 12.9 years).
Table 4 NMR lipoprotein profile performed on whole plasma
Girl Boy Mother Father
Normal,*
Mean 6 SD
VLDL and chylomicron concentrations, nmol/L
VLDLCP 121.5† 65.4† 27.4† 82.1† 77.3 6 65.5
VLCP 118.2† 44.7† 4.5† 12.4† 3.0 6 7.7
VMP 0† 0† 15.7† 58.1† 46.7 6 52.2
VSP 3.3† 20.7† 7.2† 15.7† 28.1 6 26
LDL particle concentrations, nmol/L
LDLP 651 621 1486 1749 1514 6 489
IDLP 80† 187† 27 84† 27 6 44
LLP 0 0 652 499 422 6 279
LSP 571 434 806 1166 1065 6 564
HDL particle concentrations, mmol/L
HDLP 20.4† 20.7† 51.8† 33.5 30.5 6 7.6
HLP 1.5† 0.4† 6.8 1.6† 7.0 6 4.6
HMP 1.1 4.2 27.2† 3.1 2.7 6 3.7
HSP 17.8 16.1 17.8 28.8 20.8 6 5.7
Mean particle sizes, nm
VZ 84.3† 83.6† 55.7 59.8 53.6 6 15.0
LZ 19.6 19.7 21.2 20.2 20.7 6 0.9
HZ 8.3 8.6 8.9 8.1 8.9 6 0.4
Lipoproteins: VLDL, very low density lipoproteins; LDL, low density lipoproteins; HDL, high density lipoproteins.
Lipoprotein Particle Concentrations: VLDLCP, total VLDL 1 chylomicrons; VLCP, large VLDL; VMP, medium VLDL; VSP, small VLDL; LDLP, total LDL;
IDLP, intermediate density lipoproteins; LLP, large LDL; LSP, small LDL; HDLP, total HDL; HLP, large HDL; HMP, medium HDL; HSP, small HDL.
Lipoprotein Particle Sizes: VZ, VLDL; LZ, LDL; HZ, HDL.
*Normal values were obtained from a control population (age 10-94 years, median 58 years).
†Abnormal values.
136 Journal of Clinical Lipidology, Vol 7, No 2, April 2013600 mg/dL and treatment was associated with decreases in
total cholesterol, and a slight increase in HDL-C, which re-
mained very low. During this time the triglyceride to cho-
lesterol ratio decreased, consistent with a decrease in
triglyceride-rich chylomicrons containing relatively more
triglyceride than cholesterol compared to VLDL.
The children’s apoC-II values were lower than the
parents. Case 1: 1.0 mg/dL, case 2: 1.1 mg/dL, mother: 2.1
mg/dL, father: 1.7 mg/dL (normal average mean: 4 mg/dL).
The low values suggested that partial deficiency could cause
the high triglyceride levels. Gene sequencing showed a
normal APOC2 gene. Lipid and apolipoprotein values
(Table 2), apolipoprotein-based lipoprotein subclasses
(Table 3), and nuclearmagnetic resonance lipoprotein profile
data (Table 4) are presented and the abnormal results are
listed in bold.Discussion
Supplementing a low-fat diet with premeal orlistat for
more than a year in siblings aged 6 and 8 years with severe
familial chylomicronemia caused by compound heterozy-
gous LPL deficiency, resulted in triglyceride-lowering and
prevention of potentially fatal pancreatitis over more than a
year of observation. Because the lipoprotein lipase defi-
ciency results in severe impairment of lipid clearance, it
follows that minimizing intestinal fat absorption byinhibiting pancreatic lipase results in triglyceride lowering.
Tzotzas et al11 reported that a 34-year-old man with famil-
ial chylomicronemia who had only a trace of LPL activity
in postheparin plasma, benefited from the same premeal
doses of orlistat given during a 12-week period with a
33% reduction in fasting triglyceride. However, use of orli-
stat for this condition has not been widely recognized and
has not been previously used to treat children with severe
inherited lipoprotein lipase deficiency.
Although the use of orlistat has been standardly quoted
in texts as being effective in treating severe hypertriglyc-
eridemia, published information has been limited. A fre-
quently quoted case report describes a 39-year-old
nonobese Asian male with combined hyperlipidemia and
an initial triglyceride of 766 mg/dL who was found to be
resistant to treatment with a reduced-fat diet and gemfi-
brozil. The addition of orlistat resulted in 70% triglyceride
lowering showing synergism, since the combination was
shown to be more effective than either drug alone.12 Al-
though the triglyceride levels did not exceed 2000 mg/dL
(22.6 mmol/L) as in cases with monogenic defects in lipo-
protein lipase activity, partial deficiency could explain his
resistance to gemfibrozil and subsequent response to the ad-
dition of orlistat. It is possible that compliance with dietary
fat restriction may offset any further response to orlistat;
however, this is not the case in our monogenic siblings,
who remain on very low fat intake while on orlistat but
respond with marked increases in triglyceride to small
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compliance with prescribed standard reductions in fat in-
take could explain the resistance to orlistat, but this
becomes apparent to the patient with the appearance of
oily stools and flatulence caused by undigested fat.
The efficacy of treatment directed at further reducing
intestinal fat in severe hypertriglyceridemia is further
suggested by observations in five adults who were reported
to have had a further 35% decrease in triglyceride after the
addition of orlistat to their existing medications13 supporting
its wider use. Pancreatic lipase inhibition with orlistat con-
trasts with conventional treatments, such as fibrates,
omega-3 fatty acids, and niacin, which have been used to in-
crease plasma triglyceride clearance and decrease hepatic
VLDL production,14–16 but these latter agents arewithout ef-
fect in familial chylomicronemia2 because defective chylo-
micron clearance by lipoprotein lipase persists and is
resistant to enhancement. On the basis of the rationale that
treatment with orlistat can reduce calories from fat ingestion,
it has also been used for weight loss in adolescent patients
who are obese,17 providing evidence that the drug can be
used at young ages with a low side-effect profile. Further-
more, previous investigators have shown antidiabetic and
antiatherogenic properties of orlistat in addition to its effect
on weight loss,18 and LDL-C can be lowered by 10%.19
Because orlistat inhibits fat absorption by about 30% in
cases with normal pancreatic lipase,20 it is advised in the
package insert that all patients take a daily multivitamin
that contains vitamins A,D, E, and K.21,22 We observed low
levels of 25(OH)D, indicating vitamin D deficiency, which
was corrected by increasing the dose. The incidence of vita-
min D deficiency in association with orlistat therapy is more
frequent than with the other fat-soluble vitamins and occurs
in 12% of adults (6.6% for placebo) and in 1.4% of adoles-
cents (1.4% for placebo); however, the required severe reduc-
tion in fat intake is more likely to cause deficiency in familial
chylomicronemia than when prescribed for obese cases
whose dietary restriction is less stringent.
In addition medium-chain triglycerides are recommen-
ded as a source of fat because they are directly metabolized
by the liver and do not form chylomicrons20; however, re-
current pancreatitis in our boy patient was not prevented
with diet and medium-chain triglycerides as the only addi-
tive. Gastrointestinal side-effects attributed to orlistat were
minimal, possibly because the fat intake remained very low,
thus minimizing the undigested fat.
Missense lipoprotein lipase mutations, G181R and
G215E, located in exon 5 in each of the parents, resulted
in mixed heterozygous deficiency in the affected children
with confirmation at the RNA level. In general lipoprotein
lipase genes cluster in exons 5 and 6,23 and it has been pro-
posed that the resulting mutant proteins are unable to
achieve or maintain normal dimer conformation and be-
come inactive.24 The father carries G181R, which is close
to the more commonly observed Gly188Glu mutation,25
and has not been described previously. The maternal muta-
tion, G215E, is located at a site determining conformationof the central catalytic domain,26 and is rare but not novel.
Although it is listed in an international database, it has not
yet been described in a peer-reviewed publication. Al-
though we have not measured lipoprotein lipase enzyme
mass and activity, confirmation by genotyping associated
with a severe clinical course was considered sufficient for
diagnosis of compound heterozygous disease. The paternal
allele caused a moderate increase in fasting triglyceride in
the father, and the mother had a random postprandial tri-
glyceride level that was greater than 2000 mg/dL although
her fasting level was normal, suggesting that her triglycer-
ide levels are susceptible to increases in the postprandial
state; furthermore, her presumed heterozygous sister has
a history of pancreatitis and severe hypertriglyceridemia.
Because both affected children had significant hyperchy-
lomicronemia shown in standing plasma and in the nuclear
magnetic resonance profile, it was of interest to observe
increases in the apolipoprotein content of the chylomicrons.
The very high apoB levels in the lipemic plasma approached
normal in chylomicron-free plasma, indicating that the
polyclonal apoB antibody detected an abundance of intesti-
nally derived apoB-48–containing chylomicrons contribut-
ing to a very high total apoB. These lipoproteins, having
undergone prolonged plasma retention secondary to the
lipoprotein lipase deficiency, are likely to contain a combi-
nation of apoB-48 originating from the intestine as chylo-
microns, and apoB-100 originating from the liver in the form
of VLDL. A relatively increased intermediate-density lipo-
protein (IDL) particle number is consistent with a large pool
of non-HDL particles including chylomicron remnants.
Total plasma apoE and apoC-III were markedly in-
creased in the chylomicrons, indicating that they acquire
apoC-III and apoE resulting in high total levels, but the
levels were normal in chylomicron-free plasma. This
finding can be explained by apoC-III and apoE not being
integrated with the particle at the time of secretion but
transferred to the chylomicrons from other lipoproteins,
including HDL.27 However, the apoC-III ratio calculated as
the proportion of apoC-III in HDL to non-HDL measured
in the heparin precipitated fraction was lower than the
cut-point, reflecting poor lipolysis of triglyceride-rich parti-
cles. This concept is supported by observations that
apoC-III normally undergoes transfer during lipolysis
proportionate to the rate of lipolysis28 and postheparin lip-
olytic activity.29 ApoE, known to have a similar bimodal
distribution to apoC-III, was also highly associated with
the chylomicrons in both affected children. The unusual
distribution can be attributed to transfer from HDL and sug-
gests that the normal protective function of apoE in enhanc-
ing remnant removal by LDL receptor uptake30 is offset by
being sequestered in chylomicrons.
Because apoA-I, like apoB, is considered an integral
apolipoprotein, transfer among lipoproteins is minimal. It
appeared normal in the boy and his parents but high in the
girl before chylomicron removal, which is consistent with a
proportion of apoA-I originating from the intestine as well
as the liver31 in the form of lipid-poor apoA-I. The apoA-II,
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cant proportion in the chylomicrons consistent with an in-
testinal origin or possibly excessive transfer from HDL.
The HDL-C was remarkably low in the affected children,
particularly in the boy, and the HDL particle concentration
was low, particularly in the large-sized particle subclass
suggesting poorly functional HDL in regard to cholesterol
enrichment by efflux from peripheral cells. Also, interac-
tion of cholesterol ester transport protein with the
triglyceride-rich particles particularly in the postprandial
state32 is likely to be associated with increased cholesterol
ester transport activity.33 Consequently HDL enrichment
with triglyceride and subsequent degradation by intact he-
patic triglyceride lipase34 probably contributes to the signif-
icant HDL-C lowering. The lower HDL-C and apoA-I in
the boy can be attributed to pubertal onset and the influence
of testosterone during puberty.35
Lipoprotein subclasses determined by serial immune-
precipitations of the respective apolipoproteins8,9 in
chylomicron-free plasma, provided further characterization
of the remaining particles and insight on long term risk for
atherosclerosis. Because apoB-containing subclasses have
variable affinities for lipoprotein lipase with LpA-
II:B:C:D:E having the least,36 the remarkably elevated
LpA-II:B:C:D:E particles in chylomicron-free plasma in
both affected children support their dependence on lipopro-
tein lipase for disposal. Resistance of triglyceride-rich lip-
oproteins to lipoprotein lipase has been previously
described37 and is considered to be an independent cause
of hypertriglyceridemia.38 LpB:C particles also are in-
creased, particularly in the boy and are associated with in-
creased cardiovascular risk supported by evidence that
apoB-containing particles that also contain apoC-III are
stronger predictors of atherosclerosis than LDL-C39 or par-
ticles that contain apoB alone.40
On the basis of our data on the subclasses determined by
apolipoprotein composition and an increase in IDL particle
concentration, it appears likely that cases with familial
chylomicronemia are at risk for premature cardiovascular
disease as previously reported in four cases,41 particularly
in the presence of low apoA-I, HDL-C, and HDL particle
concentration. Although we reduced the risk of pancreatitis
by triglyceride-lowering, the HDL-C remained low as
shown by routine follow-up lipid profile testing (Table 1),
suggesting that cardiovascular risk was unchanged by orli-
stat. Other than detailed studies on a single posttreatment
sample, the follow-up studies were confined to lipid profiles
and LDL-C could not be derived because of the hypertri-
glyceridemia. However, the lipoprotein particle data de-
rived from a single posttreatment chylomicron-free
plasma sample (Tables 2 and 3) support attention to cardi-
ovascular risk factors, lifestyle prescription and appropriate
treatment when indicated.
Because heterozygous lipoprotein lipase deficiency is
estimated to be present in less than 1 in 500 people, cases
have been detected and studied more frequently after initial
observations that they can manifest as familial combinedhyperlipidemia and may be at significant risk for cardio-
vascular disease,42 particularly if risk factors such as ab-
dominal obesity, hyperinsulinemia, estrogen treatment, or
excess alcohol intake are present.38 This was evident in
the maternal aunt who by history developed adverse risk
factors followed by severe hypertriglyceridemia associated
with episodes of pancreatitis and more recently has ac-
quired type 2 diabetes. Parental lipid profiles showed
mild fasting hypertriglyceridemia in the father associated
with mild increases in apoC-III in the heparin-
precipitated apoB-containing fraction, consistent with
increased cardiovascular risk.39 Also, his LDL and IDL par-
ticle concentrations were above the mean and greater than
in the mother, although she was observed to have postpran-
dial hypertriglyceridemia (triglyceride .2000 mg/dL) in a
random sample drawn at a clinic visit.
After more than a year of observation, we conclude that
the addition of orlistat to a low-fat diet is effective and safe
in reducing fasting triglyceride levels and the risk for
pancreatitis in siblings with severe compound heterozygous
lipoprotein lipase deficiency. However, despite intensive
dietary fat restriction and pancreatic lipase inhibition with
orlistat, HDL-C remains low and lipoprotein abnormalities
are present in chylomicron-free plasma that could lead to
long-term cardiometabolic risk in the affected children and
to some extent in their carrier parents. These observations
support careful monitoring of cardiovascular risk, lifestyle
prescription and additional treatment when indicated.Acknowledgments
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